Clinical Trial

Chemotherapy Induced Peripheral Neuropathy by Taxanes and Capsaicin 8%.

Study acronym: capsaNeP
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this study is to compare the evolution of the density of small nerve fibers assessed with skin biopsies at the foot between two groups of patients with taxane-induced chronic neuropathic pain matched for sex and age: one group treated with applications of capsaicin 8% and a control group who received a systemic treatment. The hypothesis for the capsaicin 8% arm is that in the chronic phase, in the absence in the nervous environment of the toxic agent (in this case taxanes) causing the neuropathy and the functional modifications at the origin of pain, the new small fibers could regenerate without these pathological alterations. Our analysis will be based on the demonstration of structural abnormalities of small nerve fibers by means of skin biopsy, but also of functional abnormalities using four validated tests commonly used in this field: quantitative sensory testing (QST), laser evoked potential recordings, Sudoscan and confocal corneal microscopy.
Trial Details
NCT Number NCT07602387
Lead Sponsor Hospital Ambroise Paré Paris
Collaborators: Institut Curie, Grünenthal GmbH
Conditions Patients With Taxane-induced Chronic Neuropathic Pain
Enrollment 50 participants
Start Date 2024-03-12
Primary Completion 2027-03 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2026-05-22